TGFB1 and pancreatic neoplasm: It is reported that lipoxin A4, as an endogenous lipoxygenase-derived eicosanoid mediator, could reverse the mesenchymal phenotype of pancreatic cancer and suppress its invasion and metastasis by inhibiting autocrine TGF-β1 signaling, and that therapeutically targeting this process may prevent pancreatic cancer metastasis (18).